Regeneron Pharmaceuticals news
Results Regeneron Pharmaceuticals has filed with the SEC, each with its AAOIFI halal screening.
- Regeneron Pharmaceuticals reports $5.12 billion revenue for quarter ended September 30, 2026, up 36.3%
- Regeneron Pharmaceuticals reports $4.29 billion revenue for quarter ended June 30, 2026, up 16.7%
- Regeneron Pharmaceuticals reports $3.61 billion revenue for quarter ended March 31, 2026, up 19%
- Regeneron Pharmaceuticals reports $14.34 billion revenue for fiscal year ended December 31, 2025, up 1%
Recent event reports (Form 8-K)
- Announced results of operations
- Entered a material agreement; Announced results of operations
- Director or senior officer change
- Announced results of operations
- Announced results of operations
- Announced results of operations
- Announced results of operations
- Announced results of operations
- Announced results of operations
- Announced results of operations
- Announced results of operations
Listed from the company's filing index on the SEC website; open the filing for the details.